{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:14:21Z","timestamp":1783383261084,"version":"3.54.6"},"reference-count":32,"publisher":"Georg Thieme Verlag KG","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hamostaseologie"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The emergence of non-factor therapies has fundamentally changed inhibitor management in haemophilia. Historically, immune tolerance induction (ITI) was considered indispensable for eradicating factor VIII (FVIII) or IX inhibitors and restoring responsiveness to replacement therapy. However, the introduction of rebalancing therapies (TFPI inhibitors, tissue factor pathway inhibitors) and emicizumab, a bispecific antibody mimicking factor VIIIa activity, provides highly effective bleed protection regardless of inhibitor status, challenging the traditional paradigm of universal ITI. Subcutaneous emicizumab and TFPI inhibitors enable safe, convenient prophylaxis without the need for central venous access or intensive FVIII respectively IX exposure, raising the question of whether ITI remains necessary in all patients with haemophilia A or B with inhibitors.<\/jats:p>\n                  <jats:p>Current ITI practice increasingly favours combined ITI\u2013emicizumab strategies, which reduce treatment burden and bleeding risk. Interim data from the MOTIVATE study and registry data indicate that combined approaches can achieve inhibitor eradication, yet success rates and optimal protocols remain uncertain. Moreover, the clinical relevance of tolerance is debated: while FVIII treatment is effective and safe to treat major bleeds or to cover major surgery compared to bypassing agents, many patients achieve good bleed protection with emicizumab prophylaxis without inhibitor eradication, but data on long-term joint health are still lacking. In haemophilia B, ITI feasibility is further limited by allergic reactions and nephrotic syndrome, making rebalancing therapies as a promising alternative for long-term care. This review explores whether ITI continues to be justified in the era of non-factor prophylaxis, summarizing evolving strategies, real-world evidence and unresolved questions.<\/jats:p>","DOI":"10.1055\/a-2887-8098","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T23:22:52Z","timestamp":1783380172000},"source":"Crossref","is-referenced-by-count":0,"title":["Update: Immune Tolerance Induction Practice in Haemophilia"],"prefix":"10.1055","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0802-5280","authenticated-orcid":false,"given":"Carmen","family":"Escuriola Ettingshausen","sequence":"additional","affiliation":[{"name":"H\u00e4mophilie Zentrum Rhein Main GmbH, Hessen, Germany","place":["Frankfurt am Main"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2026,7,6]]},"reference":[{"issue":"20","key":"ref1","doi-asserted-by":"publisher","first-page":"4046","DOI":"10.1182\/blood-2012-09-457036","article-title":"Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study","volume":"121","author":"S C Gouw","year":"2013","journal-title":"Blood"},{"issue":"01","key":"ref2","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3324\/haematol.2019.234914","article-title":"Inhibitor incidence in an unselected cohort of previously untreated patients with severe hemophilia B: a PedNet study","volume":"106","author":"C Male","year":"2021","journal-title":"Haematologica"},{"issue":"13","key":"ref3","doi-asserted-by":"publisher","first-page":"2732","DOI":"10.1182\/bloodadvances.2021004718","article-title":"Final results of the PUPs B-LONG study: evaluating safety and efficacy of rFIXFc in previously untreated patients with hemophilia B","volume":"5","author":"B Nolan","year":"2021","journal-title":"Blood Adv"},{"issue":"06","key":"ref4","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1111\/hae.14391","article-title":"Immune tolerance induction in the era of emicizumab \u2013 still the first choice for patients with haemophilia A and inhibitors?","volume":"27","author":"K Holstein","year":"2021","journal-title":"Haemophilia"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1159\/000031073","article-title":"Induction of immune tolerance in haemophilia A inhibitor patients by the \u2018Bonn protocol\u2019: predictive parameter for therapy duration and outcome","volume":"77","author":"J Oldenburg","year":"1999","journal-title":"Vox Sang"},{"issue":"05","key":"ref6","first-page":"525","article-title":"Immune tolerance therapy in paediatric haemophilia A patients with factor VIII inhibitors: 20 years\u2019 experience","volume":"86","author":"W Kreuz","year":"2001","journal-title":"Haematologica"},{"issue":"06","key":"ref7","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1182\/blood-2011-08-369132","article-title":"The principal results of the international immune tolerance study: a randomized dose comparison","volume":"119","author":"C RM Hay","year":"2012","journal-title":"Blood"},{"issue":"16","key":"ref8","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1182\/blood.2020009511","article-title":"Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies","volume":"137","author":"M U Callaghan","year":"2021","journal-title":"Blood"},{"issue":"04","key":"ref9","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1111\/hae.13763","article-title":"The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab","volume":"25","author":"M Carcao","year":"2019","journal-title":"Haemophilia"},{"issue":"05","key":"ref10","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1111\/hae.13819","article-title":"Immune tolerance induction in paediatric patients with haemophilia A and inhibitors receiving emicizumab prophylaxis","volume":"25","author":"G Batsuli","year":"2019","journal-title":"Haemophilia"},{"issue":"06","key":"ref11","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1111\/hae.14381","article-title":"Immune tolerance induction in severe haemophilia A: a UKHCDO inhibitor and paediatric working party consensus update","volume":"27","author":"D P Hart","year":"2021","journal-title":"Haemophilia"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1177\/20406207211032452","article-title":"Design of an international investigator-initiated study on modern treatment of inhibitor-positive patients with haemophilia A (MOTIVATE)","volume":"12","author":"C Escuriola Ettingshausen","year":"2021","journal-title":"Ther Adv Hematol"},{"issue":"8044","key":"ref13","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/S0140-6736(77)90871-6","article-title":"Massive factor VIII infusion in haemophiliac with factor VIII inhibitor, high responder","volume":"2","author":"H H Brackmann","year":"1977","journal-title":"Lancet"},{"issue":"07","key":"ref14","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1160\/TH16-12-0934","article-title":"Factor VIIIa-mimetic co-factor activity of a bispecific antibody to factors IX\/IXa and X\/Xa, emicizumab, depends on its ability to bridge the antigens","volume":"117","author":"T Kitazawa","year":"2017","journal-title":"Thromb Haemost"},{"issue":"09","key":"ref15","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab prophylaxis in hemophilia A with inhibitors","volume":"377","author":"J Oldenburg","year":"2017","journal-title":"N Engl J Med"},{"issue":"24","key":"ref16","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1182\/blood.2019001869","article-title":"A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors","volume":"134","author":"G Young","year":"2019","journal-title":"Blood"},{"issue":"06","key":"ref17","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1111\/hae.13846","article-title":"A multicentre, open-label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia A without inhibitors","volume":"25","author":"M Shima","year":"2019","journal-title":"Haemophilia"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH guidelines for the Management of Hemophilia, 3rd edition","volume":"26","author":"A Srivastava","year":"2020","journal-title":"Haemophilia"},{"issue":"04","key":"ref19","doi-asserted-by":"publisher","first-page":"102926","DOI":"10.1016\/j.rpth.2025.102926","article-title":"Activated prothrombin complex concentrate in patients receiving emicizumab prophylaxis: from evidence to clinical practice","volume":"9","author":"R F Sidonio Jr","year":"2025","journal-title":"Res Pract Thromb Haemost"},{"issue":"03","key":"ref21","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1046\/j.1365-2516.1999.00311.x","article-title":"German recommendations for immune tolerance therapy in type A haemophiliacs with antibodies","volume":"5","author":"H H Brackmann","year":"1999","journal-title":"Haemophilia"},{"issue":"03","key":"ref22","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1182\/blood.V86.3.983.983","article-title":"Low-dose immune tolerance induction in hemophilia A patients with inhibitors","volume":"86","author":"E P Mauser-Bunschoten","year":"1995","journal-title":"Blood"},{"issue":"05","key":"ref23","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1111\/hae.12730","article-title":"US guidelines for immune tolerance induction in patients with haemophilia A and inhibitors","volume":"21","author":"L A Valentino","year":"2015","journal-title":"Haemophilia"},{"issue":"01","key":"ref24","first-page":"32","article-title":"Tolerance induction in haemophilia A patients with inhibitors: Malm\u00f6 protocol update","volume":"5","author":"C Freiburghaus","year":"1999","journal-title":"Haemophilia"},{"issue":"02","key":"ref25","first-page":"155","article-title":"Immune tolerance induction in haemophilia B patients with inhibitors: the Beutel protocol","volume":"29","author":"K Beutel","year":"2009","journal-title":"Haemostaseologie"},{"issue":"01","key":"ref26","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/hae.12263","article-title":"Primary and rescue immune tolerance induction in children and adults: a multicentre international study with a VWF-containing plasma-derived FVIII concentrate","volume":"20","author":"J Oldenburg","year":"2014","journal-title":"Haemophilia"},{"issue":"02","key":"ref27","doi-asserted-by":"publisher","first-page":"e124","DOI":"10.1055\/s-0042-1748756","article-title":"Immune tolerance induction (ITI) with a pdFVIII\/VWF concentrate (octanate) in 100 patients in the observational ITI (ObsITI) study","volume":"6","author":"C Escuriola Ettingshausen","year":"2022","journal-title":"TH Open"},{"issue":"03","key":"ref29","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1111\/hae.12608","article-title":"Prompt immune tolerance induction at inhibitor diagnosis regardless of titre may increase overall success in haemophilia A complicated by inhibitors: experience of two U.S. centres","volume":"21","author":"C Nakar","year":"2015","journal-title":"Haemophilia"},{"issue":"03","key":"ref30","doi-asserted-by":"publisher","first-page":"e305","DOI":"10.1111\/hae.14291","article-title":"Optimizing the management of patients with haemophilia A and inhibitors in the era of emicizumab: recommendations from a German expert panel","volume":"27","author":"C Escuriola-Ettingshausen","year":"2021","journal-title":"Haemophilia"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1365-2516.2007.01497.x","article-title":"International workshop on immune tolerance induction: consensus recommendations","volume":"13","author":"D M DiMichele","year":"2007","journal-title":"Haemophilia"},{"issue":"14","key":"ref33","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1182\/blood.2024027468","article-title":"Marstacimab prophylaxis in hemophilia A\/B without inhibitors: results from the phase 3 BASIS trial","volume":"146","author":"D Matino","year":"2025","journal-title":"Blood"},{"issue":"09","key":"ref34","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJMoa2216455","article-title":"Phase 3 trial of Concizumab in Hemophilia with inhibitors","volume":"389","author":"T Matsushita","year":"2023","journal-title":"N Engl J Med"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtha.2025.09.038","article-title":"Concizumab use in toddlers with hemophilia B and inhibitors: real-world data from an international collaboration","author":"S Levy-Mendelovich","year":"2025","journal-title":"J Thromb Haemost"}],"container-title":["H\u00e4mostaseologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2887-8098.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T23:22:54Z","timestamp":1783380174000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2887-8098"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,6]]},"references-count":32,"URL":"https:\/\/doi.org\/10.1055\/a-2887-8098","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0720-9355","2567-5761"],"issn-type":[{"value":"0720-9355","type":"print"},{"value":"2567-5761","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,6]]}}}